496 related articles for article (PubMed ID: 34943877)
1. Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson's Disease.
Eyer GC; Di Santo S; Hewer E; Andereggen L; Seiler S; Widmer HR
Cells; 2021 Nov; 10(12):. PubMed ID: 34943877
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
3. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
5. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
7. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.
Watts PM; Riedl AG; Douek DC; Edwards RJ; Boobis AR; Jenner P; Marsden CD
Neuroscience; 1998 Sep; 86(2):511-9. PubMed ID: 9881865
[TBL] [Abstract][Full Text] [Related]
8. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease.
Shehadeh J; Double KL; Murphy KE; Bobrovskaya L; Reyes S; Dunkley PR; Halliday GM; Dickson PW
Neurobiol Dis; 2019 Oct; 130():104524. PubMed ID: 31276794
[TBL] [Abstract][Full Text] [Related]
9. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
Ding YX; Xia Y; Jiao XY; Duan L; Yu J; Wang X; Chen LW
Neurochem Res; 2011 Oct; 36(10):1759-66. PubMed ID: 21562748
[TBL] [Abstract][Full Text] [Related]
10. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
11. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
12. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
14. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
[TBL] [Abstract][Full Text] [Related]
15. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons.
Chen L; Liu C; Xue Y; Chen XY
Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783
[TBL] [Abstract][Full Text] [Related]
16. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
17. Loss of Nogo-A-expressing neurons in a rat model of Parkinson's disease.
Schawkat K; Di Santo S; Seiler S; Ducray AD; Widmer HR
Neuroscience; 2015 Mar; 288():59-72. PubMed ID: 25554426
[TBL] [Abstract][Full Text] [Related]
18. Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.
Swanson C; Emborg M
Neurol Res; 2014 Jul; 36(7):634-46. PubMed ID: 24620964
[TBL] [Abstract][Full Text] [Related]
19. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
20. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
